Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.

Okada, Tadashi

Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats. [electronic resource] - Clinical and experimental nephrology Oct 2009 - 438-446 p. digital

Publication Type: Journal Article

1437-7799

10.1007/s10157-009-0196-0 doi


Animals
Antibiotics, Antineoplastic--toxicity
Antidiuretic Hormone Receptor Antagonists
Benzazepines--therapeutic use
Desmin--metabolism
Humans
Intracellular Signaling Peptides and Proteins--metabolism
Kidney Glomerulus--cytology
Male
Membrane Proteins--metabolism
Nephrosis--chemically induced
Organ Size
Podocytes--drug effects
Puromycin Aminonucleoside--toxicity
Rats
Rats, Sprague-Dawley
Tolvaptan
WT1 Proteins--metabolism